World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
35405
World Ranking
10013
National Ranking
5153

Tapan M. Kadia publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Tapan M. Kadia sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,715 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Tapan M. Kadia D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Tapan M. Kadia sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Tapan M. Kadia is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a significant concentration in Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health, and Oncology. Their work encompasses a broad range of topics related to leukemia and other hematological malignancies.

Key areas of study for Kadia include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Protein Degradation and Inhibitors

Their recent publications reflect contributions to understanding acute myeloid leukemia and related treatments, including:

  • "Acute myeloid leukemia: current progress and future directions," 2021, Blood Cancer Journal
  • "Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges," 2020, Cancer Discovery
  • "Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia," 2021, Journal of Clinical Oncology
  • "10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial," 2020, The Lancet Haematology
  • "De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017," 2021, Cancer

Frequent co-authors contributing to their body of work include:

  • Farhad Ravandi
  • Courtney D. DiNardo
  • Hagop M. Kantarjian
  • Nicholas J. Short
  • Guillermo Garcia-Manero

Tapan M. Kadia's publications are often found in prominent hematology and oncology journals. Notable publication venues with the highest number of their contributions include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • American Journal of Hematology
  • HemaSphere

Best Publications

  • Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

    Marina Konopleva;Daniel A. Pollyea;Jalaja Potluri;Brenda Chyla

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

    Naval Daver;Guillermo Garcia-Manero;Sreyashi Basu;Prajwal C Boddu

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

    Hagop M. Kantarjian;Susan OBrien;Elias Joseph Jabbour;Guillermo Garcia-Manero

  • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

    Hagop M. Kantarjian;Farhad Ravandi;Susan OBrien;Jorge Cortes

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

    Nitin Jain;Audrey V. Lamb;Susan O’Brien;Farhad Ravandi

  • Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

    Courtney D. DiNardo;Farhad Ravandi;Sam Agresta;Marina Konopleva

  • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study

    Elias Jabbour;Hagop Kantarjian;Farhad Ravandi;Deborah Thomas

  • Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab

    Yasmin Abaza;Hagop M. Kantarjian;Guillermo Garcia-Manero;Elihu Estey

  • Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

    Nicholas J. Short;Marina Konopleva;Tapan M. Kadia;Gautam Borthakur

  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

    Courtney D DiNardo;Abhishek Maiti;Caitlin R Rausch;Naveen Pemmaraju

  • Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Naval Daver;Deborah Thomas;Farhad Ravandi;Jorge Cortes

  • Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

    Hagop Kantarjian;Farhad Ravandi;Nicholas J Short;Xuelin Huang

  • Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

    Srdan Verstovsek;Hagop M. Kantarjian;Zeev Estrov;Jorge E. Cortes

  • TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

    Tapan M. Kadia;DM Preetesh Jain Md;Farhad Ravandi;Guillermo Garcia-Manero

  • Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

    Courtney D. DiNardo;Curtis A. Lachowiez;Koichi Takahashi;Sanam Loghavi

Frequent Co-Authors

Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Keyur P. Patel
Keyur P. Patel The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Kapil N. Bhalla
Kapil N. Bhalla The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean pursuing an MD. Today, a range of accredited online degrees empower students to enter rewarding healthcare fields with greater flexibility and often at a lower cost.

Those interested in mental health can earn advanced practice credentials through psych np programs, which prepare you for roles as Psychiatric Nurse Practitioners. Another popular route is healthcare management. If you’re aiming for operational or leadership positions, a bachelors in health administration provides a strong foundation in organizational strategy, public health, and policy.

Professionals seeking to advance may choose a master’s degree. The cheapest mha programs online healthcare offer affordability as well as specialization in critical administrative skills. For clinical leadership and the highest level of nursing practice, the best dnp programs online are designed to foster innovation and evidence-based care.

These online pathways can open doors to upward mobility and help address the nation’s evolving healthcare needs, all while accommodating busy student schedules.

Best Scientists Citing Tapan M. Kadia

Trending Scientists

Recently Published Articles